Last year, a phase III trial demonstrated Nexavar (sorafenib) tablets significantly extended progression-free survival in locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
Top-line results from a phase III trial evaluating the addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet its primary endpoint of a statistically significant improvement in overall survival in men with metastatic castrate-resistant prostate cancer when compared to docetaxel/prednisone alone.
FDA approved Cyramza (ramucirumab) to treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma.
Last week, a blistering opinion piece on The New York Times editorial page focused on the coziness of the relationship between the American Cancer Society and Walgreens. The piece initially triggered criticism by ACS officials, but then—with no fanfare whatsoever—the society’s CEO called on the drug store chain, as well as others, to stop selling tobacco […]
CCOP Letter to VarmusThe letter to Varmus was signed by 56 of the 64 CCOP PIs.
The Gap OpensMany doctors who participate in CCOPs commit money from their practices to this endeavor. Institutions, too, end up having to throw in subsidies.
THE AMERICAN ASSOCIATION FOR CANCER RESEARCH is now accepting applications for the Stand Up To Cancer-Cancer Research U.K. Translational Research Fellowship, which will provide up to four grants for postdoctoral or clinical research fellows, each up to $315,000, over a four-year period.
MD ANDERSON CANCER CENTER formed a research alliance with GlaxoSmithKline to strengthen its efforts in advancing anticancer immunotherapies.
BECKY DEKAY was named president of the Association of Community Cancer Centers at its annual meeting April 2. She is director of oncology services at the Feist-Weiller Cancer Center at LSU Health Shreveport.
